| scholarly article | Q13442814 |
| P50 | author | Craig Venter | Q311003 |
| Rino Rappuoli | Q2154243 | ||
| Philip R Dormitzer | Q101423214 | ||
| Bolyn Hubby | Q125172038 | ||
| George F. Gao | Q16260071 | ||
| P2093 | author name string | Ethan C Settembre | |
| Domenico Maione | |||
| Peter W Mason | |||
| Christian W Mandl | |||
| Yuelong Shu | |||
| Daniel G Gibson | |||
| Giuseppe Palladino | |||
| Zhi-Qing Qi | |||
| Sylvie Bertholet | |||
| Jeffrey B Ulmer | |||
| Ennio De Gregorio | |||
| Nicky C Caiazza | |||
| Luis A Brito | |||
| Scilla Buccato | |||
| Michela Brazzoli | |||
| Armin Hekele | |||
| Jun Urano | |||
| Alessandra Bonci | |||
| Daniele Casini | |||
| Andrew J Geall | |||
| Jacob Archer | |||
| Gillis R Otten | |||
| John E Gill | |||
| P2860 | cites work | DNA vaccine manufacture: scale and quality | Q37590348 |
| RNA-based vaccines | Q38006567 | ||
| RNA: the new revolution in nucleic acid vaccines | Q38111853 | ||
| Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids | Q40391286 | ||
| Inactivated influenza vaccines. 2. Laboratory indices of protection | Q41243525 | ||
| Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus | Q43030850 | ||
| Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children | Q43963300 | ||
| New influenza A (H1N1) virus: global epidemiological situation, June 2009 | Q84084159 | ||
| An alternative renewable source of squalene for use in emulsion adjuvants | Q84490646 | ||
| DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials | Q85047234 | ||
| RNA vaccine | Q85795487 | ||
| Lessons from pandemic influenza A(H1N1): The research-based vaccine industry's perspective | Q22251431 | ||
| Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study | Q28269717 | ||
| Human infection with a novel avian-origin influenza A (H7N9) virus | Q29620049 | ||
| Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome | Q30223081 | ||
| Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. | Q30369679 | ||
| Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. | Q30383794 | ||
| The first influenza pandemic of the new millennium | Q30401658 | ||
| New technologies for influenza vaccines | Q30411859 | ||
| Influenza: options to improve pandemic preparation | Q30418373 | ||
| Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection | Q30423733 | ||
| Real-time numerical forecast of global epidemic spreading: case study of 2009 A/H1N1pdm. | Q30424718 | ||
| Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses | Q30427591 | ||
| Synthetic generation of influenza vaccine viruses for rapid response to pandemics | Q30430578 | ||
| Haemagglutination-inhibiting antibody to influenza virus | Q35747515 | ||
| Messenger RNA-based vaccines | Q35842616 | ||
| Long-term storage of DNA-free RNA for use in vaccine studies | Q35920469 | ||
| Nonviral delivery of self-amplifying RNA vaccines | Q36221799 | ||
| An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector | Q36524157 | ||
| Vaccination with messenger RNA (mRNA). | Q37028853 | ||
| Nucleic acid isothermal amplification technologies: a review | Q37079972 | ||
| Vaccines: correlates of vaccine-induced immunity | Q37193062 | ||
| P433 | issue | 8 | |
| P921 | main subject | data sharing | Q5227350 |
| P304 | page(s) | e52 | |
| P577 | publication date | 2013-08-14 | |
| P1433 | published in | Emerging Microbes & Infections | Q27724513 |
| P1476 | title | Rapidly produced SAM(®) vaccine against H7N9 influenza is immunogenic in mice. | |
| P478 | volume | 2 |
| Q56341976 | A Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against Zika |
| Q90779652 | A Trans-amplifying RNA Vaccine Strategy for Induction of Potent Protective Immunity |
| Q38206520 | A development that may evolve into a revolution in medicine: mRNA as the basis for novel, nucleotide-based vaccines and drugs |
| Q37681765 | Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge |
| Q63246270 | Advances in mRNA Vaccines for Infectious Diseases |
| Q41919615 | Antibody Immunity Induced by H7N9 Avian Influenza Vaccines: Evaluation Criteria, Affecting Factors, and Implications for Rational Vaccine Design |
| Q90104786 | Biomedical applications of mRNA nanomedicine |
| Q30357413 | Bringing influenza vaccines into the 21st century. |
| Q38853141 | CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes |
| Q92945120 | Co-administration of GM-CSF expressing RNA is a powerful tool to enhance potency of SAM-based vaccines |
| Q28082744 | Delivering vaccines to the people who need them most |
| Q37126611 | Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose |
| Q98613812 | Development of a potent Zika virus vaccine using self-amplifying messenger RNA |
| Q38205757 | Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. |
| Q36500269 | Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens |
| Q41993335 | Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques |
| Q57059896 | Engineered mRNA-expressed antibodies prevent respiratory syncytial virus infection |
| Q90228087 | Enlisting the mRNA Vaccine Platform to Combat Parasitic Infections |
| Q90384384 | Establishing Preferred Product Characterization for the Evaluation of RNA Vaccine Antigens |
| Q36218294 | Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes |
| Q47633699 | From empiricism to rational design: a personal perspective of the evolution of vaccine development |
| Q42364268 | GISAID: Global initiative on sharing all influenza data - from vision to reality |
| Q58606318 | Heterologous Immunization With Defined RNA and Subunit Vaccines Enhances T Cell Responses That Protect Against |
| Q40415200 | Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens |
| Q39310460 | Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection. |
| Q30380290 | Induction of Broad-Based Immunity and Protective Efficacy by Self-amplifying mRNA Vaccines Encoding Influenza Virus Hemagglutinin |
| Q37737615 | Induction of Protective Immunity against Toxoplasma gondii in Mice by Nucleoside Triphosphate Hydrolase-II (NTPase-II) Self-amplifying RNA Vaccine Encapsulated in Lipid Nanoparticle (LNP). |
| Q47112853 | Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells. |
| Q30367695 | Influenza vaccines: a moving interdisciplinary field. |
| Q40405921 | Measuring the Adjuvant Activity of RNA Vaccines |
| Q40049416 | Modified mRNA Vaccines Protect against Zika Virus Infection |
| Q39027005 | Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease |
| Q89861258 | Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives |
| Q39091854 | Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems |
| Q56363429 | Neutralization of the Plasmodium-encoded MIF ortholog confers protective immunity against malaria infection |
| Q52609655 | New Kids on the Block: RNA-Based Influenza Virus Vaccines. |
| Q57072744 | New Vaccine Technologies to Combat Outbreak Situations |
| Q91511819 | Nonclinical safety assessment of repeated administration and biodistribution of a novel rabies self-amplifying mRNA vaccine in rats |
| Q52599675 | Novel Platforms for the Development of a Universal Influenza Vaccine. |
| Q38199151 | Nucleic acid vaccines: prospects for non-viral delivery of mRNA vaccines |
| Q40405926 | Nucleoside Modified mRNA Vaccines for Infectious Diseases |
| Q35558828 | Potent immune responses in rhesus macaques induced by nonviral delivery of a self-amplifying RNA vaccine expressing HIV type 1 envelope with a cationic nanoemulsion |
| Q30401521 | Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses |
| Q47257240 | Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses. |
| Q91631072 | Self-Amplifying RNA Vaccines for Venezuelan Equine Encephalitis Virus Induce Robust Protective Immunogenicity in Mice |
| Q36104042 | Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge |
| Q100946403 | Self-amplifying RNA vaccines for infectious diseases |
| Q38255634 | Self-replicating alphavirus RNA vaccines. |
| Q64058331 | Structural Insights for Anti-Influenza Vaccine Design |
| Q40654970 | Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences |
| Q30148631 | Tackling a novel lethal virus: a focus on H7N9 vaccine development. |
| Q42696034 | The 'anti-hype' vaccine |
| Q40405913 | The European Regulatory Environment of RNA-Based Vaccines |
| Q49829267 | The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases |
| Q91695398 | The Skin You Are In: Design-of-Experiments Optimization of Lipid Nanoparticle Self-Amplifying RNA Formulations in Human Skin Explants |
| Q33739733 | The notorious R.N.A. in the spotlight - drug or target for the treatment of disease |
| Q38867794 | Toward RNA nanoparticle vaccines: synergizing RNA and inorganic nanoparticles to achieve immunopotentiation |
| Q30386388 | Universal influenza vaccines: Shifting to better vaccines. |
| Q90754855 | Unlocking the potential of vaccines built on messenger RNA |
| Q30390904 | Vaccines, new opportunities for a new society |
| Q91901320 | mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases |
| Q27469050 | mRNA capping: biological functions and applications |
| Q33711685 | mRNA vaccine delivery using lipid nanoparticles |
| Q47736893 | mRNA vaccines - a new era in vaccinology |
| Q38252360 | mRNA-based therapeutics--developing a new class of drugs |
Search more.